The expanded facility will add additional capacities and capabilities to support Pfizer’s growing gene therapy unit.
The Sanford-based plant currently manufactures therapies for hemophilia B and Duchenne muscular dystrophy, among other gene therapies.
The expanded facility will create about 300 jobs.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
